Hepatology

Recent research highlights the discovery of 17 novel loci associated with liver triglycerides and 9 linked to liver inflammation.

Recent studies have highlighted the potential of sodium-glucose cotransporter 2 inhibitors, especially ertugliflozin, in improving outcomes for patients with NAFLD and T2DM.

Frailty has emerged as a therapeutic target in advanced chronic liver disease management, with non-pharmacological interventions showing promise.

Lifestyle modifications, particularly dietary changes, have shown potential in reversing MASLD and steatohepatitis.

A recent clinical trial investigated combining time-restricted feeding and flaxseed for MASLD treatment.

Among serum biomarkers, the FIB-4 and APRI scores are widely recognised for assessing advanced fibrosis and cirrhosis.

This study examined the efficacy and safety of pemafibrate in 360 patients with MASLD and hypertriglyceridaemia.

The study involved 419 patients, aged 18–75, with noncirrhotic PSC, who were randomly assigned to receive either cilofexor or a placebo over 96 weeks.